Archives of Physical Medicine and Rehabilitation
Volume 90, Issue 7 , Pages 1094-1101 , July 2009

Periodic Salbutamol in Facioscapulohumeral Muscular Dystrophy: A Randomized Controlled Trial

  • C.A. Payan, MD

      Affiliations

    • Institute of Myology, Hospital Pitié-Salpêtrière, Paris, France
    • Corresponding Author InformationCorrespondence to C.A. Payan, MD, Institut de Myologie, Groupe Hospitalier Pitié-Salpêtrière, Batiment Babinski, 47 bd de l'Hôpital, 75651 Paris Cedex 13, France
    • ,
  • J.Y. Hogrel, PhD

      Affiliations

    • Institute of Myology, Hospital Pitié-Salpêtrière, Paris, France
    • ,
  • E.H. Hammouda, MD

      Affiliations

    • Association Française contre les Myopathies (AFM), Evry, France
    • ,
  • L. Lacomblez, MD

      Affiliations

    • Department of Neurology, Hospital Pitié-Salpêtrière, AP-HP; University Pierre & Marie Curie UPMC Paris 6; INSERM UMR 678; Paris, France
    • ,
  • G. Ollivier, PT

      Affiliations

    • Institute of Myology, Hospital Pitié-Salpêtrière, Paris, France
    • ,
  • V. Doppler, MD

      Affiliations

    • Institute of Myology, Hospital Pitié-Salpêtrière, Paris, France
    • ,
  • B. Eymard, MD, PhD

      Affiliations

    • Reference Center of Neuromuscular Disorders Paris-Est, Hospital Pitié-Salpêtrière, AP-HP; University Pierre & Marie Curie UPMC Paris 6; Paris, France
    • ,
  • S. Attarian, MD

      Affiliations

    • Reference Center for Neuromuscular Disorders & Amyotrophic Lateral Sclerosis, University Hospital La Timone, AP-HM, Marseille, France
    • ,
  • J. Pouget, MD, PhD

      Affiliations

    • Reference Center for Neuromuscular Disorders & Amyotrophic Lateral Sclerosis, University Hospital La Timone, AP-HM, Marseille, France
    • ,
  • C. Desnuelle, MD, PhD

      Affiliations

    • Reference Center for Neuromuscular Disorders & Amyotrophic Lateral Sclerosis, Hospital l'Archet, Nice, France
    • ,
  • P. Laforêt, MD

      Affiliations

    • Reference Center of Neuromuscular Disorders Paris-Est, Hospital Pitié-Salpêtrière, AP-HP, Paris, France

References 

  1. Padberg GW. Facioscapulohumeral disease. Leiden: Leiden University; 1982;
  2. van Deutekom JC, Wijmenga C, van Tienhoven EA, et al. FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit. Hum Mol Genet. 1993;2:2037–2042
  3. Martineau L, Horan MA, Rothwell NJ, Little RA. Salbutamol, a beta 2-adrenoceptor agonist, increases skeletal muscle strength in young men. Clin Sci (Lond). 1992;83(5):615–621
  4. Yang YT, McElligott MA. Multiple actions of beta-adrenergic agonists on skeletal muscle and adipose tissue. Biochem J. 1989;261:1–10
  5. Maltin CA, Delday MI, Watson JS, et al. Clenbuterol, a beta-adrenoceptor agonist, increases relative muscle strength in orthopaedic patients. Clin Sci (Lond). 1993;84(6):651–654
  6. Collomp K, Candau R, Lasne F, Labsy Z, Prefaut C, De Ceaurriz J. Effects of short-term oral salbutamol administration on exercise endurance and metabolism. J Appl Physiol. 2000;89(2):430–436
  7. Kissel JT, McDermott MP, Natarajan R, et al. Pilot trial of albuterol in facioscapulohumeral muscular dystrophy (FSH-DY Group). Neurology. 1998;50(5):1402–1406
  8. Kissel JT, McDermott MP, Mendell JR, et al. Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy. Neurology. 2001;57:1434–1440
  9. van der Kooi EL, Vogels OJ, van Asseldonk RJ, et al. Strength training and albuterol in facioscapulohumeral muscular dystrophy. Neurology. 2004;63:702–708
  10. Rothwell NJ, Stock MJ, Sudera DK. Changes in tissue blood flow and beta-receptor density of skeletal muscle in rats treated with the beta2-adrenoceptor agonist clenbuterol. Br J Pharmacol. 1987;90:601–607
  11. Hogrel JY, Payan CA, Ollivier G, et al. Development of a French isometric strength normative database for adults using quantitative muscle testing. Arch Phys Med Rehabil. 2007;88:1289–1297
  12. Duncan ND, Williams DA, Lynch GS. Deleterious effects of chronic clenbuterol treatment on endurance and sprint exercise performance in rats. Clin Sci (Lond). 2000;98(3):339–347
  13. Sykes RS, Reese ME, Meyer MC, Chubb JM. Relative bioavailability of a controlled-release albuterol formulation for twice-daily use. Biopharm Drug Dispos. 1988;9:551–556
  14. A prospective, quantitative study of the natural history of facioscapulohumeral muscular dystrophy (FSHD): implications for therapeutic trials (The FSH-DY Group). Neurology. 1997;48:38–46
  15. Milroy R, Carter R, Carlyle D, Boyd G. Clinical and pharmacological study of a novel controlled release preparation of salbutamol. Br J Clin Pharmacol. 1990;29:578–580
  16. Lipworth BJ, Clark RA, Dhillon DP, Charter MK, Palmer JB, McDevitt DG. Single dose and steady-state pharmacokinetics of 4 mg and 8 mg oral salbutamol controlled-release in patients with bronchial asthma. Eur J Clin Pharmacol. 1989;37:49–52
  17. Maesen FP, Smeets JJ. Comparison of a controlled-release tablet of salbutamol given twice daily with a standard tablet given four times daily in the management of chronic obstructive lung disease. Eur J Clin Pharmacol. 1986;31:431–436
  18. van der Kooi EL, Kalkman JS, Lindeman E, et al. Effects of training and albuterol on pain and fatigue in facioscapulohumeral muscular dystrophy. J Neurol. 2007;254:931–940
  19. Skura CL, Fowler EG, Wetzel GT, Graves M, Spencer MJ. Albuterol increases lean body mass in ambulatory boys with Duchenne or Becker muscular dystrophy. Neurology. 2008;70:137–143
  20. Kinali M, Mercuri E, Main M, et al. Pilot trial of albuterol in spinal muscular atrophy. Neurology. 2002;59:609–610
  21. Fowler EG, Graves MC, Wetzel GT, Spencer MJ. Pilot trial of albuterol in Duchenne and Becker muscular dystrophy. Neurology. 2004;62:1006–1008
  22. Messina S, Hartley L, Main M, et al. Pilot trial of salbutamol in central core and multi-minicore diseases. Neuropediatrics. 2004;35(5):262–266
  23. Dupont-Versteegden EE, Katz MS, McCarter RJ. Beneficial versus adverse effects of long-term use of clenbuterol in mdx mice. Muscle Nerve. 1995;18:1447–1459
  24. Escolar DM, Buyse G, Henricson E, et al. CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy. Ann Neurol. 2005;58:151–155
  25. Vincent KA, Carr AJ, Walburn J, Scott DL, Rose MR. Construction and validation of a quality of life questionnaire for neuromuscular disease (INQoL). Neurology. 2007;68:1051–1057
  26. Berard C, Payan C, Hodgkinson I, Fermanian J. A motor function measure for neuromuscular diseases (Construction and validation study). Neuromuscul Disord. 2005;15:463–470

 Supported by the Association Française contre les Myopathies (AFM grant no. 6742) and sponsored by the Assistance Publique Hôpitaux de Paris (AP-HP, PHRC grant no. AOM98125).

 No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit on the authors or on any organization with which the authors are associated.

 Reprints are not available from the author.

PII: S0003-9993(09)00208-1

doi: 10.1016/j.apmr.2008.12.027

Archives of Physical Medicine and Rehabilitation
Volume 90, Issue 7 , Pages 1094-1101 , July 2009

Article Tools

* Image Usage & Resolution